Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (49)	5/12/2001 11:58:06 PM
From: keokalani'nui	Respond to of 1840

No. I mean to call them. Selective disclosure and all. W

To: Miljenko Zuanic who wrote (49)	5/13/2001 1:07:28 PM
From: tuck	Read Replies (1) \| Respond to of 1840

You guys have any thoughts on CEGE's results? To my untrained eye, the major responses for these refractory patients look good. However, these are interim results with a small population, and I don't know the field that well. Message 15794007 TIA & Cheers, Tuck

To: Miljenko Zuanic who wrote (49)	5/16/2001 1:55:10 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 1840

Miljenko, >>Any luck with SCIO?<< Apparently the company was promoting its drug discovery and development capabilities and used P38 merely as an example of its skill. The company did not provide anything more than was disclosed in previous PI P38 announcement. Makes me think management engaged in a little puffery when on the CC it even bothered to mention the "presention on P38" in London. IR read the slides to me over the phone, and there was nothing of interest in them. Nice conversation w/IR anyway. I'm surprised if they can get any work done before May 25. Wilder